To understand the development of Alzheimer's through molecular structure

Scientists at the University of Washington School of Medicine have detailedly analyzed the molecular structure of Alzheimer's disease through recombinant rat proteins. Understanding the molecular structure (and the effect of genetic mutations on the molecular structure) can help to understand the development of Alzheimer's and other neurodegenerative diseases and how to prevent and treat them.

It has been recognized and supported that molecular TREM2 is related to cognitive decline and is a sign of neurodegenerative diseases, including Alzheimer's disease. In previous studies, some mutations alter the structure of TERM2, thereby increasing the risk of disease or developing Alzheimer's disease, dementia, Parkinson's syndrome, amyotrophic lateral sclerosis (ALS), etc. Other TREM2 mutations with a rare genetic disease Nasu-Hakola will lead to dementia, and most patients would not outlive 50 years old.

"We do not have an accurate picture of the effects of abnormal TERM2 on neurodegeneration, but we know that inflammation is a big threat in any case. And if we can master its own protein structure and how it affects its function, we are looking for ways to set things right." said the team leader.

TREM2 is located on the surface of the immune system of small glial, and it is called the important "housekeeper" cells. By phagocytosis, it forms β amyloid protein of Alzheimer's disease and other substances. If the microglia lacks TREM2, or if TREM2 is dysfunctional, the cell steward can't perform a cleanup task.

"What TREM2 has done remains unresolved, but we know that TREM2 can't keep the brain healthy in mice," says the team leader. "Now that we have understood the molecular structure of TREM2, we can go one step further to study its role in neurodegenerative diseases."

In addition, she added that TREM2 is also associated with a number of other inflammatory diseases, including chronic obstructive pulmonary disease and stroke. Therefore, understanding the structure of TREM2 can be important for the understanding of systemic degenerative diseases. Flarebio offers recombinant proteins of good quality such as recombinant Itgb1.

Scientists develop new way of diagnosing diseases

Maybe you never thought that music and genes can be linked together, but the combination of the two may be able to change the medical diagnosis in the future. Music and genes are repetitive, and the number of choices is limited. A gene has 4 base pairs, and music has 12 kinds of notes. This logic is used to transform protein structures into melodies so that they are no longer passed through the eyes but analyzed with the ears. Researchers who put this idea say that their melodies can be used to teach protein science and can be used to determine mutations in the near future.

Researchers at the University of Tampere in Finland, the University of East Washington and the Francis Crick Institute in London, England, conducted research using recombinant horse proteins and believed that their technology can help scientists more easily identify abnormalities in proteins. "We believe that in the future, people will eventually hear the data and extract important information from it," says Jonathan Middleton, Ph.D. of the University of East Washington. "The ear may detect more information than the eye. If the ear can do that, then you can liberate your eyes and pay more attention to other things."

Proteins have many different functions, and they are usually studied through observation under the microscope with the eyes. Now, researchers use an "audible" technique to convert protein data information into melodies. The study, published in the journal Heliyon, aims to answer three main questions: What does the data sound like? Are there any benefits? Can we hear the anomaly from the data?

An introductory excerpt shows the melody of the 1r75 protein. Researchers hope that someday other molecules can also be converted to melodies or they can even "listen" to the complete genome. This melody was created by the combination of Dr. Middleton's compositional techniques and algorithms so that other people could use a similar process to write melodies for proteins. When people hear these melodies, a large number of people can recognize the connection between tone and vision (such as images and tables), which means "listening" proteins are simpler than imagined. According to them, these melodies sound wonderful, which can also encourage scientists to listen several times to more accurately analyze the protein. The protein data information is converted to melody using an "audible" technique.

"Protein folding is one of the most annoying parts of the molecular biology field," says Dr. Robert Bywater of the Francis Crick Institute. "Researchers need to identify not only the type of folding but also the clues to its many functions." Information is not easy, and music acts as a power to achieve the release of this information.

Researchers say their melodies can be used to teach protein science and to determine mutations in the near future. But its application is not limited to proteins. Researchers hope that in the future one day other molecules can also be converted to music and "audible" technique even can be used to listen to the entire genome. This multidisciplinary approach (combining genetics and music) provides a new perspective on the complex issues of biology. If you’re do related research, recombinant proteins including recombinant Itgb1 from Flarebio will be good choices for you.

New therapeutic target of type 2 diabetes: decomposition of branched chain amino acid

A study published today in the Journal of the Public Library of Science has identified five genetic variations associated with higher levels of the branched-chain amino acids isoleucine, leucine and valine. Through research using recombinant rat proteins, the researchers also found that these gene mutations are associated with an increased risk of type 2 diabetes.

A team led by the Department of Epidemiology at the University of Cambridge Medical Research Council (MRC) made use of large-scale genetic data and detailed measurements of branched-chain amino acids and their metabolites in more than 16,000 volunteers.

Branched chain amino acids play a fundamental role in human metabolism, and it is the basis of protein. Unlike the other 20 amino acids, they can't be produced by the human body. This means that their level depends entirely on external resources (food sources or dietary supplements) and the body's metabolic capacity.

Up to now, although higher circulating levels of branched-chain amino acids have been found to be associated with type 2 diabetes, no study has been able to determine whether the association is causal. This is important because if found to be causally related, dietary intake reductions or changes in the metabolism of these amino acids may help to prevent the growing prevalence of diabetes and the severity of the disease.

Researchers studied more than 10 million genetic variations in more than 16,000 men and women and found genetic differences in five human genomic regions associated with higher levels of circulating branched-chain amino acids. They then found that in 300,000 people, including 40,000 people with diabetes, those with genetic differences associated with higher levels of branched-chain amino acids were at higher risk of developing type 2 diabetes, providing strong evidence of causality.

The PPM1K gene has been found to have the strongest association with all three amino acid levels and a higher risk of developing diabetes, and can encode a known regulator that plays a pivotal role in the breakdown of branched-chain amino acids. This suggests that impaired decomposition of these amino acids may make individuals at higher risk of developing type 2 diabetes. Intervention on this pathway may reduce the risk of diabetes.

"Our results suggest that therapeutic strategies for the metabolism of branched-chain amino acids can help to reduce the risk of diabetes, which we already know about," said Claudia Langenberg, MD from the MRC Epidemiology Unit at the University of Cambridge. Clinical trials are now needed to determine whether drugs that break down on branched-chain amino acids can reduce the risk of type 2 diabetes. Flarebio provides superior recombinant proteins like recombinant ITGB1 at great prices.

These antibiotics can also be cheaper and easier to treat tuberculosis!

Scientists have taken an important step in designing a new antibiotic to fight resistant bacterial infections, such as tuberculosis. In the study of natural chemical biology using recombinant mouse proteins, they described these new compounds to attack previous non-targeted enzymes, which are important for building and sustaining the cell wall of bacteria. The team said that these antibiotics can also be cheaper and easier to treat tuberculosis (TB).

The treatment of MDR-TB is costly. In addition, the treatment takes a long time and do harm to human body, and it has potentially life-threatening side effects. "One of the reasons for the new study is that more than half of the antibiotics given to patients today are of the β-lactam class," said Gyanu Lamichhane, associate professor of medicine at the Johns Hopkins University School of Medicine in Baltimore. These drugs paly their role by destroying DD-transpeptidase enzyme, while this enzyme is essential for the construction and maintenance of bacterial cell walls. Without enzymes, the bacteria die quickly.

However, about 10 years ago, the researchers discovered another enzyme called LD-transpeptidase - also important for the cell wall - is an antibiotic that allows bacteria such as TB to survive. In new research - in a complex imaging system, with the help of a protein called X-ray crystallography, the team investigated the detailed molecular structure of the LD-transpeptidase extracted from various bacteria.

With knowledge about the structure of the new enzyme, the researchers then tested the molecules that might work on it. They tested new compounds from beta-lactam antibiotic subclasses that specifically bind to new enzymes. By using live bacterial cultures, they show that compounds called carbapenems block wall-building enzymes. This also suggests that CDC, called the ESKAPE pathogen, works in a group of bacteria and is considered a particular threat because of its ability to resist drug resistance.

The team also tested two carbapenems in different groups of TB-infected mice. They found that even without the use of classical tuberculosis antibiotics, new compounds - especially ibuprofen - had a better therapeutic effect on tuberculosis in mice. "Our data show that carbapenem successfully treats tuberculosis infection by attacking enzymes," said Professor Lamichhane. The team is now planning clinical trials to test the safety and efficacy of some of these new compounds. Flarebio provides good-quality recombinant proteins like recombinant Itgb1 at competitive prices.